secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2023-08-17T23:59:59+00:00
Accession:  0001517022-23-000029
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia receives Nasdaq deficiency notice for late Q2 filing; plans to file by Aug 25
--------------------------------------------------------------------------------

- Form 10-Q for Q2 2023 not filed on time; Nasdaq gave non-compliance notice on Aug 11, 2023.
- Accounting errors identified regarding return reserves for Auryxia in prior financial statements.
- Company has 60 days to submit a plan; expects to file Form 10-Q by August 25, 2023.
- Common stock continues trading on Nasdaq; Akebia expects to regain compliance upon filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000029/0001517022-23-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000029/akba-20230811.htm
  HTML page:      https://secwatch.observer/filing/0001517022-23-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer